A5001669965- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Urinary Bladder and Prostate Research
- Cancer, Lipids, and Metabolism
- Urological Disorders and Treatments
- Pediatric Urology and Nephrology Studies
- Cancer Immunotherapy and Biomarkers
- Cardiac, Anesthesia and Surgical Outcomes
- PARP inhibition in cancer therapy
- Statistical Methods in Clinical Trials
- Urologic and reproductive health conditions
- Urinary Tract Infections Management
- Urinary and Genital Oncology Studies
- Surgical Simulation and Training
- Pelvic floor disorders treatments
- Cancer Genomics and Diagnostics
- Sexual function and dysfunction studies
- Ureteral procedures and complications
- Kidney Stones and Urolithiasis Treatments
- Multiple Myeloma Research and Treatments
Michigan Institute of Urology
2016-2025
Beaumont Hospital, Troy
2008-2024
Corewell Health
2022-2024
Oakland University
2013-2024
Beaumont Health
2014-2023
Beaumont Hospital, Royal Oak
2010-2023
Cranbrook Academy of Art
2019
Royal Oak Community Coalition
2012-2018
Lipella Pharmaceuticals (United States)
2015
University of Pittsburgh
2015
Non-clear cell renal carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis aggressive disease, therapeutic targets to complement immunotherapy are current clinical needs. Multi-omics analyses 48 non-ccRCCs compared with 103 ccRCCs reveal proteogenomic, phosphorylation, glycosylation, metabolic aberrations in RCC subtypes. RCCs high genome instability display overexpression IGF2BP3 PYCR1. Integration...
Associate Editor Ash Tewari Editorial Board Ralph Clayman, USA Inderbir Gill, Roger Kirby, UK Mani Menon, OBJECTIVES To detail the technique and evaluate in a preliminary study effectiveness of posterior reconstruction Denonvilliers’ musculofascial plate (PRDMP) enhancing early continence after robotic laparoscopic radical prostatectomy (RP). PATIENTS AND METHODS Thirty‐two consecutive patients having or RP with PRDMP (group 1). Thirty previous not were compared as historical controls 2)....
Half of patients with muscle-invasive bladder cancer worldwide may not receive curative-intent therapy. Elderly or frail are most affected by this unmet need. TAR-200 is a novel, intravesical drug delivery system that provides sustained, local release gemcitabine into the over 21-day dosing cycle. The phase 1 TAR-200-103 study evaluated safety, tolerability, and preliminary efficacy in who either refused were unfit for therapy.Eligible had cT2-cT3bN0M0 urothelial carcinoma bladder. was...
OBJECTIVE To report on the initial four patients who had robotic salvage retropubic prostatectomy (SRP) for biochemical recurrence after radiation therapy, and to review surgical outcome of cystoprostatectomy bladder cancer in two previously prostate cancer. PATIENTS AND METHODS Since February 2006, SRP failure and/or brachytherapy. Transrectal biopsy confirmed locally recurrent disease a metastatic evaluation including bone scan computed tomography abdomen pelvis were negative all cases....
Background and Purpose: Coexisting renal calculus disease may pose technical challenges in the surgical management of ureteropelvic junction obstruction. We report our experience with laparoscopic pyelolithotomy at time pyeloplasty compare outcome data a cohort patients undergoing without coexistent stone disease. Patients Methods: reviewed on 117 last 3 years institution. Fifteen (10.6%) underwent concomitant ipsilateral pyeloplasty. Laparoscopic graspers alone were used 11 (73.3%)...
We primarily determined whether the small animal radiation research platform could create a rat cystitis model via targeted bladder irradiation (phase I). The response to treating early phase in rats with transurethral catheter instillation of liposomal tacrolimus was also examined II).In I 16 adult female Sprague Dawley® were used. Metabolic urination patterns analyzed before and after exposure 20, 30 or 40 Gy radiation. In II irradiated randomly assigned receive single saline...
The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to evolve. Sipuleucel-T was the first immunotherapy approved by US Food and Drug Administration (FDA) treat asymptomatic or minimally symptomatic mCRPC. androgen receptor-targeting agents (ARTAs) abiraterone acetate enzalutamide were initially Looking at chemotherapy-naïve men with mCRPC, we compared survival outcomes between sipuleucel-T + ARTA cohort (men who received either an in line, then other...
Abstract Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play role in DNA repair. The phase II QUEST study evaluated NIRA combinations patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations had progressed on 1 prior line novel androgen receptor-targeted therapy. Results from the combination abiraterone acetate plus prednisone, disrupts axis...
Introduction and Objectives: Aquablation (Aqua) is a novel technique for treating benign prostatic hyperplasia lower urinary tract symptoms. This study compares Aqua to simple prostatectomy (SP), analyzing functional outcomes, adverse events (AE), retreatment rates. Methods: A single-institution retrospective chart review was conducted men undergoing open/robotic SP or from 2017 2023 prostates >80 mL. Data collected included blood transfusions, AE, rates, postoperative medication use,...
Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, the only oral ADT, with limited real-world data on persistence and adherence. This retrospective study evaluates adherence of relugolix, degarelix, GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using from IBM MarketScan Research Database (Jan 2017 - Dec 2022). The (1 January 31 December 2022) was used enrollment history claims....
No AccessJournal of UrologyAdult Urology: Oncology: Renal/Upper Tract/Bladder1 May 2005DOES BODY MASS INDEX AFFECT SURVIVAL OF PATIENTS UNDERGOING RADICAL OR PARTIAL CYSTECTOMY FOR BLADDER CANCER? JASON HAFRON, NANDITA MITRA, GUIDO DALBAGNI, BERNARD BOCHNER, HARRY HERR, and S. MACHELE DONAT HAFRONJASON HAFRON , MITRANANDITA MITRA DALBAGNIGUIDO DALBAGNI BOCHNERBERNARD BOCHNER HERRHARRY HERR DONATS. View All Author Informationhttps://doi.org/10.1097/01.ju.0000154352.54965.14AboutFull TextPDF...
To present our initial series of robotic-assisted retroperitoneal dismembered pyeloplasty in adults patients using the da Vinci Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA).Ten adult with unilateral ureteropelvic junction (UPJ) obstruction underwent retroperitoneoscopic Anderson-Hynes between February 2004 and March 2005. UPJ was primary six secondary four after failed endopyelotomy. Dismembered performed utilizing a approach (developed by balloon dissection). Three laparoscopic...